Breve descripción
The purpose of this study is to measure the change in proteinuria and its impact on the rates of partial and complete remission in patients with primary FSGS or MCD with frexalimab, brivekimig, or rilzabrutinib compared with placebo
Médico del ensayo / Coordinador del estudio
Roxy Ni
Estimated Enrollment
84
Estimated End Date
September 2026
Trial is for people with
Primary Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
Study Goal
This study wants to learn more about how 3 investigational drugs, frexalimab, brivekimig, or rilzabrutinib works in the body, how much ...
What is involved for the patient?
Patients will be asked to allow researchers to access medical history, to provide truthful information about their medical ...
About the drug or intervention
frexalimab, Brivekimig, and Rilzabrutinib are study drugs developed by the Sponsor to treat various autoimmune diseases. They each ...